远程和局部的Aβ有助于阿尔茨海默病的传播
1School of Medicine, Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran 14496-14535, Iran.
Cerebral cortex (New York, N.Y. : 1991)
|September 27, 2024
概括
在阿尔茨海默氏症 (AD) 中,粉样β病理远程和局部促进通过大脑连接传播. 这解释了粉样蛋白-β如何影响的总体运动,尽管有空间差异,提供了对AD进展的新见解.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 医疗成像医学成像
背景情况:
- 阿尔茨海默氏病 (AD) 涉及粉样β斑块的积累,先于聚合物的积累和传播.
- 粉样β和病理之间的空间差异引发了关于它们的相互作用和传播机制的问题.
研究的目的:
- 为了研究粉样β如何促进在阿尔茨海默病中通过神经元连接传播.
- 阐明新皮层粉样β影响早期病理性tau及其在皮层区域的传播的机制.
主要方法:
- 使用功能磁共振成像 (fMRI) 规范连接体和纵向体内分子成像数据.
- 分析了来自阿尔茨海默氏病神经成像计划的317名参与者的成像数据 (173名粉样蛋白-beta阴性,144名粉样蛋白-beta阳性).
- 通过使用静止状态fMRI连接体,模拟的tau通过功能连接传播.
主要成果:
- 在高沉积区域 (地震中心) 的粉样蛋白-β显示与基于连接的tau病理传播的远程关联.
- 粉样蛋白-β在病态性最高的区域 (中) 与基于连接性的扩散到其他区域的增加相关.
- 研究结果表明,粉样β病理在远程和局部地促进基于连接的tau聚合物的传播.
结论:
- 解释了粉样蛋白-β如何影响陶聚合物的扩散,尽管空间不一致.
- 突出了神经元连接在调解粉样β对病理进展的影响中的作用.
- 通过了解粉样β在促进tau传播中的作用,建议潜在的治疗点.
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K


